Trial Profile

A clinical study of of CTA313 in patients with SLE/LN.

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 04 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CTA 313 (Primary) ; Cyclophosphamide; Fludarabine
Indications Lupus nephritis; Systemic lupus erythematosus
Focus Adverse reactions

Most Recent Events

04 Dec 2025 New trial record
30 Oct 2025 According to Imviva Biotech media release, data from this study were presented at ACR.
30 Oct 2025 Results published in the Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com